Identifying and targeting determinants of melanoma cellular invasion
Aparna Jayachandran(The University of Melbourne), Sonja J. McKeown(Discovery Institute), Jonathan Cebon(La Trobe University), Andreas Behren(The University of Melbourne), Prashanth Prithviraj(The University of Melbourne), Pu‐Han Lo(Ludwig Cancer Research), Matthew Anaka(Ludwig Cancer Research), Marzena Walkiewicz(Ludwig Cancer Research), BeeShin Tan(The University of Melbourne), Briannyn Woods(The University of Melbourne)
Cited by 49
Related Papers
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
|Proceedings of the National Academy of Sciences|2004|440
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
|The Lancet Oncology|2017|247
Macrophage Migration Inhibitory Factor Induces Macrophage Recruitment via CC Chemokine Ligand 2
|The Journal of Immunology|2006|229
Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes
|Brain Communications|2020|199